PMID: 2504263Aug 1, 1989Paper

Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics

British Heart Journal
J A TillD W Holt

Abstract

Twenty three children with recurrent supraventricular tachycardia were treated with flecainide. Twenty one of these received intravenous treatment during an attack (2 mg/kg over 10 minutes). The tachycardia was terminated in 17. After an intravenous bolus of flecainide, blood samples were drawn at regular intervals for analysis of flecainide concentration over 48 hours. Pharmacokinetic variables were calculated--median terminal half life 7.5 hours, median volume of distribution 6.2 l/kg, and median plasma clearance 7.2 ml/min/kg. There was a significant correlation between half life and age. Twenty of the children received long term treatment with an oral preparation of flecainide to prevent further attacks. Twelve had no further attacks and 16 were considered to have good control. Two children suffered potentially serious arrhythmogenic effects soon after the start of oral treatment and flecainide had to be stopped. During oral treatment regular blood samples were drawn and plasma concentrations were analysed to assess the therapeutic range. This did not differ substantially from that proposed in adults (400-800 micrograms/l). Eight children were electively withdrawn from oral flecainide to see whether they really needed it. B...Continue Reading

References

Jan 1, 1987·Journal of the American College of Cardiology·A A de PaolaH R Kay
Feb 1, 1987·British Heart Journal·C Wren, R W Campbell
Mar 1, 1987·Archives of Disease in Childhood·J A TillD E Ward
Jul 3, 1986·The New England Journal of Medicine·D M Roden, R L Woosley
Sep 1, 1986·Journal of the American College of Cardiology·J MorganrothG D Gentzkow
Oct 1, 1985·British Journal of Clinical Pharmacology·A JohnstonP Turner
May 1, 1983·Journal of Pharmacological Methods·A Johnston, R C Woollard
Feb 27, 1984·The American Journal of Cardiology·N A EstesJ N Ruskin

❮ Previous
Next ❯

Citations

Sep 1, 2005·Pediatric Cardiology·V V DimasK E Ward
Jun 27, 1992·Lancet·J Till, A Herxheimer
Apr 1, 1995·Journal of the American College of Cardiology·A L FenrichR A Friedman
Oct 1, 1995·Journal of the American College of Cardiology·J J O'SullivanC Wren
Feb 2, 2002·Journal of the American College of Cardiology·Jack F PriceArnold L Fenrich
May 24, 2000·Progress in Pediatric Cardiology·J P Moak
May 24, 2000·Progress in Pediatric Cardiology·A Dubin
Feb 1, 1994·Acta Paediatrica Japonica; Overseas Edition·Z IsmailA Jamaluddin
Feb 24, 2006·Archives of Disease in Childhood. Fetal and Neonatal Edition·D S Kothari, J R Skinner
May 1, 1991·Archives of Disease in Childhood·J A Till, E A Shinebourne
Sep 3, 2010·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·M C TaveraR Tumbarello
Sep 30, 2010·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Maria Cristina TaveraRoberto Tumbarello
Mar 25, 2008·Early Human Development·Jonathan R Skinner, Gurleen Sharland
Jun 1, 1990·International Journal of Cardiology·T G Losekoot, W L Lubbers
Mar 21, 2009·Journal of Cardiovascular Medicine·Marco FerliniGian B Danzi
Aug 13, 2009·The Annals of Pharmacotherapy·Lisa C A D'AlessandroIlan Buffo-Sequiera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.